The immediate follow-on offering after earnings suggests urgent capital needs despite improved cash runway. The 10.6% discount to market price indicates weak investor demand. Traders should monitor cash burn rate and trial enrollment progress, as the company will need substantial additional funding beyond 2029 to complete development and commercialization. The timing suggests management may be capitalizing on temporary market optimism before potential trial setbacks.
Price Chart
Executive Summary
Trevi Therapeutics priced a $150.8 million follow-on offering of 11.6 million shares at $13.00 per share, just one day after reporting earnings. The proceeds will fund clinical development of its lead candidate Haduvio through 2029, covering pivotal Phase 3 trials for IPF-related chronic cough and Phase 2b trials for non-IPF ILD and RCC indications. This offering follows a recent $150 million shelf registration and comes amid concerns about capital needs despite a preliminary cash balance of $171.8 million as of March 31, 2026.
Key Facts
- Offered 11,600,000 shares of common stock at $13.00 per share, raising $150.8 million in gross proceeds
- Offering priced one day after earnings release (April 17, 2026 8-K filing)
- Proceeds of approximately $141.1 million (after expenses) will fund clinical development of Haduvio through 2029
- Funds expected to cover Phase 3 trials for IPF-related chronic cough and Phase 2b trials for non-IPF ILD and RCC indications
- Preliminary cash balance as of March 31, 2026 was $171.8 million
- Shares offered at $13.00 despite a closing price of $14.54 on April 16, 2026, representing a 10.6% discount
- Significant immediate dilution of $10.68 per share to new investors
Financial Impact
$150.8 million raised through issuance of 11.6 million shares at $13.00 per share, with net proceeds of approximately $141.1 million after expenses
Risk Factors
- Significant dilution to existing shareholders
- Company will need substantial additional funding beyond 2029 to complete development and commercialization
- Clinical trial delays or failures could significantly impact valuation
- Weak pricing (10.6% discount to market) suggests limited investor demand
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-161582 |
| Document: d106297dexfilingfees.htm | 0001193125-26-161582 |
| Document: 0001193125-26-161582-index-headers.html | 0001193125-26-161582 |
| Document: 0001193125-26-161582-index.html | 0001193125-26-161582 |
| Document: 0001193125-26-161582.txt | 0001193125-26-161582 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 11, 2026 16w ago | Institutional Cluster | $13.46 $17.26 | ▲ +28.23% | ▲ +23.84% | $13.91 (+3.34%) |
Jun 11, 2026 16w ago | Institutional Cluster | $13.46 $17.26 | ▲ +28.23% | ▲ +23.84% | $13.91 (+3.34%) |
Apr 21, 2026 23w ago | DEFA14A | $14.80 $19.07 | ▲ +28.85% | ▲ +24.07% | $13.91 (−6.01%) |
Apr 20, 2026 23w ago | Press Release | $14.62 $17.36 | ▲ +18.74% | ▲ +11.84% | $13.91 (−4.86%) |
Apr 17, 2026 24w ago | 424B5 | $15.40 $18.15 | ▼ −17.82% | ▼ −11.05% | $13.91 (+9.68%) |
Apr 17, 2026 24w ago | 8-K | $15.23 $17.91 | ▼ −17.60% | ▼ −11.45% | $13.91 (+8.67%) |
Apr 17, 2026 24w ago | Press Release | $15.23 $17.91 | ▲ +17.60% | ▲ +11.45% | $13.91 (−8.67%) |
Mar 17, 2026 28w ago | Press Release | $10.69 $13.46 | ▲ +25.91% | ▲ +14.39% | $13.91 (+30.12%) |
Mar 10, 2026 29w ago | Press Release | $11.94 $13.45 | ▲ +12.65% | ▲ +1.12% | $13.91 (+16.50%) |
Mar 9, 2026 29w ago | Press Release | $11.70 $13.50 | ▲ +15.38% | ▲ +3.40% | $13.91 (+18.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access